Skip to main content
. 2017 Jul 27;8(52):89539–89551. doi: 10.18632/oncotarget.19647

Figure 6. EGFR-dependent cells were sensitive to YAP1 inhibitors.

Figure 6

A. HCC827 and B. PC9 cells (exon 19 deletion) were sensitive to EGFR TKIs, afatinib and gefitinib, and were also sensitive to dasatinib. C. H1975 (L858R and T790M) and D. human primary culture CLH21 (L858R and T790M) cells were insensitive to gefitinib due to T790M but were sensitive to afatinib and dasatinib. The error bar represents the S.E. (n = 3). *P < 0.05 vehicle control compared with gefitinib; #P<0.05 compared with afatinib and *P < 0.05 compared with dasatinib treatment. E. and F. Gefitinib and afatinib reduced YAP1 expression in an EGFR-dependent manner in HCC827 cells, while gefitinib had little effects on H1975 cells EGFR phosphorylation and YAP1 expression. Dasatinib reduced YAP1 level in an EGFR-independent manner in both HCC827 and H1975 cells. EGFR-dependent cells were also sensitive to YAP1 inhibitors, verteporfin or fluvastatin with reduced cell viability in G. HCC827 or H. H1975 cells. The error bar represents the S.E. (n = 3). *P < 0.05 vehicle control compared with verteporfin; #P < 0.05 compared with fluvastatin. Reduced YAP1 protein expressions in the presence of verteporfin (1 μM) or fluvastatin (1 μM) were detected in I. HCC827 and J. H1975 cells 48 h after treatment.